# UKHSA's Vaccine Development and Evaluation Centre (VDEC) Source: https://www.keypedia.com/records/uk_mhra_guidance/uk-mhra/bf177f88-5ff8-4a56-b8f6-3d45ffe44fa8 Type: Detailed Guide Published: August 6, 2023 Updated: January 10, 2025 > The Vaccine Development Evaluation Centre (VDEC), part of the UK Health Security Agency (UKHSA), is a critical scientific hub dedicated to the development and evaluation of vaccines to combat infectious diseases and pandemic threats. As this document is a promotional and informational overview rather than an enforcement report, it does not list specific inspection dates, violations, or mandatory corrective actions. Instead, it highlights VDEC’s commitment to high quality standards and its utilization of the UK’s most extensive biosecure laboratory infrastructure, featuring biosafety levels (BSL) 2, 3, and 4. Operating within the UK's regulatory and public health framework, VDEC employs over 200 scientists who manage approximately 100 projects annually. Their expertise covers the entire vaccine lifecycle, including discovery, pre-clinical modeling, clinical testing, and post-licensure surveillance. Key focus areas include antimicrobial resistance, high-consequence infectious diseases, and innovative technologies like 'organ-on-a-chip' systems. The document serves as an invitation for industry and academic partners to collaborate with VDEC to de-risk product pipelines and bolster national pandemic preparedness. Organizations are encouraged to contact the UKHSA to access these resources and contribute to global health security. --- ## Content Work with VDEC We work with industry, academia and government. Contact UKHSA today to see how we can help you. Get in touch What VDEC does The Vaccine Development Evaluation Centre ( VDEC ) provides high-quality, cutting-edge science, building on over 100 years of innovative scientific research. Working with partners, VDEC ’s skills and resources enable the development of the vaccines we urgently need to save lives and mitigate the harm from vaccine-preventable disease. We are actively seeking national and international collaborations and partnerships from all sectors. VDEC factsheet What is VDEC PDF , 894 KB , 2 pages This file may not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use. De-risk your product pipeline VDEC ’s high containment biosecure laboratory capabilities (biosafety level (BSL) 2, 3 and 4), are the most extensive of their kind in the UK. They provide a focal point for accelerating the development of: pre-clinical models in vitro assays countermeasures for pathogens of pandemic potential, high-consequence infectious diseases and high-risk infectious diseases Scientists working in a Class III secure microbiological safety cabinet What we offer We offer access to the expertise of over 200 highly trained scientists who run approximately 100 projects per year in 2 state-of-the-art laboratories. We work across the vaccine and therapeutic lifecycle from discovery through clinical testing to post-licensure, all to the appropriate quality standards. We can support you through: Discovery and surveillance Antimicrobial resistance ( AMR ) Pre-clinical Clinical Post-licensure Novel and dangerous pathogen training Case studies VDEC ’s innovative tool for combatting antimicrobial resistance in TB Working towards a maternal vaccine for Group B Streptococcus VDEC rapidly develops an immunoassay for Mpox during the 2022 global outbreak VDEC Pre-clinical team helps to develop organ-on-a-chip to protect human health Partnerships and projects We work closely with international partners and a range of academic bodies. Find out more about partnerships and collaborations on vaccine development and evaluation See our work Microphysiological systems: how ‘organ on a chip’ technology is changing science Over 150,000 mpox vaccines ordered as UK anticipates new strain of virus Huge vaccine centre launched to bolster UK’s pandemic preparedness Chief Executive Dr Jenny Harries unveils our latest research facility, the Robinson Building ## Attachments - [What is VDEC](https://assets.publishing.service.gov.uk/media/663a38d28603389a07a6d1c8/VDEC-Factsheet.pdf)